Home › Breast Cancer › NCT06749210
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
DANCE-BASED AVENUES TO ADVANCE NONPHARMACOLOGIC TREATMENT OF CHEMOTHERAPY EFFECTS (DAANCE): A MULTICENTER TRIAL
Who can join
Ages 40 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease * completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago) * symptomatic for chemotherapy-induced neuropathy (self-report) * postural control score that indicates potential fall-risk * able to understand and comply with directions associated with testing and study treatments Exclusion Criteria: * pre-existing vestibular dysfunction * poorly controlled diabetes (hgA1C\>=8) * non-ambulatory (assistive and prosthetic devices allowed) * hearing impairment resulting in less than 10% hearing bilaterally * contraindication to participate in the experimental physical activity per the treating oncologist due to additional condition (e.g., herniated disc, unstable bone metastases) * currently in activity-based therapy (e.g., physical therapy, occupational therapy). May enroll if still meet eligibility criteria once activity-based therapy is complete.
About the study
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
What is being tested
- Tango (behavioral)
Sponsor: Ohio State University Comprehensive Cancer Center · Participants: 140 · Started: Feb 19, 2025
Contact the study team
- Lise Worthen-Chaudhari, PhD, MFA, CMES · Phone: (1) + 614-293-6281
Official record on ClinicalTrials.gov — NCT06749210
Locations in the U.S.
| Connecticut | Yale University, New Haven |
| Ohio | The Ohio State University, Columbus |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.